Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Figures & data

Table 1. Patient and clinical characteristics at the start of baricitinib treatment.

	Total
Characteristic	(n = 170)
Age in years, mean (SD)	39.3 (13.5)
Sex, proportion female	59%
Time since AD diagnosis in years, mean (SD)	20.9 (14.0)
Time since baricitinib initiation in months, median (IQR)	4 (2.3–7.0)
Patients with family history of AD, proportion	47%
BSA at baricitinib initiation, mean (SD)	8.1% (8.3)
BSA ≥ 10%, proportion	28%
Patient global assessment of AD at baricitinib initiation, proportion	Moderate: 19%
	Severe: 79%
Itch numerical rating scale (0–10) at baricitinib initiation, mean (SD), range	6.8 (2.0), 0–10
Sleep disturbance numerical rating scale (0–10) at baricitinib initiation, mean (SD), range	5.1 (2.4), 0–9

AD: atopic dermatitis; BSA: body surface area; SD: standard deviation.

Table 2. Comorbidities reported by patients with AD on baricitinib.

Comorbidities reported	n (%)
Proportion of patients with at least 1 comorbidity	90% (n = 153)
Proportion of patients with ≥2 comorbidities	67% (n = 114)
Proportion of patients with at least 1 atopic comorbidity	71% (n = 120)
Proportion of patients with 1 atopic comorbidity	32% (n = 55)
Proportion of patients with at least 1 psychiatric comorbidity	30% (n = 51)
Allergic Rhinitis (Hay fever)	53% (n = 90)
Asthma	27% (n = 46)
Anxiety	26% (n = 44)
Food allergy	23% (n = 39)
Psoriasis	15% (n = 26)
Hypertension (High blood pressure)	14% (n = 23)
Allergic conjunctivitis	12% (n = 21)
Chronic hand eczema	12% (n = 20)
Obesity	10% (n = 17)
Depression	8% (n = 14)
Alopecia Areata	7% (n = 12)
Recurrent herpes simplex (cold sores/genital herpes)	7% (n = 12)
Rheumatoid Arthritis	6% (n = 11)
Thyroid disease	6% (n = 10)
Eczema Herpeticum	5% (n = 9)
Chronic urticaria (Hives)	4% (n = 6)
Diabetes	2% (n = 4)
Heart disease or other cardiovascular condition	2% (n = 4)
Herpes Zoster (Shingles)	2% (n = 4)
None of the above	10% (n = 17)

Multiple selections were permitted for this question; patients could report that they suffered from more than one comorbidity.

Table 3. Reason for stopping prior treatment^a and treatments received prior to baricitinib inititation.

				Proption on treatment for specified durations, %(n)
Reason for stopping prior treatment (n = 162), %(n)		Prior treatment^a	%(n)	≤1 month	2 3 months	4 6 months	7 12 months	> 1 year
Did not clear skin sufficiently	61% (99)	Topical corticosteroids	76% (130)	0% (0)	5% (7)	4% (5)	12% (15)	79% (103)
Physician recommended I change	54% (88)	Topical calcineurin inhibitors inhibitors	26% (44)	2% (1)	2% (1)	9% (4)	25% (11)	61% (27)
Effect did not last/stopped working	45% (73)	Emollients	73% (124)	1% (1)	2% (3)	1% (1)	2% (3)	94% (116)
Did not have desired impact on flares	43% (69)	Systemic Antihistamines	42% (72)	0% (0)	4% (3)	3% (2)	14% (10)	79% (57)
Did not reduce symptoms	36% (59)	Systemic Corticosteroids	18% (30)	3% (1)	3% (1)	10% (3)	30% (9)	53% (16)
Did not tolerate well/had side effects	28% (45)	Systemic Immunosuppressant (oral or injection)^b	28% (48)	2% (1)	0% (0)	23% (11)	38% (18)	38% (18)
Preferred a different administration method (e.g., tablet, injection)	23% (38)	Biologics	34% (57)	0% (0)	2% (1)	28% (16)	46% (26)	25% (14)
Did not work fast enough	18% (29)	Systemic Retinoids	4% (6)	0% (0)	0% (0)	50% (3)	17% (1)	33% (2)
Fear of possible side effect	17% (28)	Phototherapy	27% (46)	7% (3)	9% (4)	13% (6)	15% (7)	57% (26)
Wanted something that required less monitoring (e.g., blood tests)	12% (20)	Alternative therapy	23% (39)	3% (1)	5% (2)	8% (3)	13% (5)	72% (28)
Preferred a different dosing frequency (e.g., daily, weekly)	10% (17)	I did not receive any treatment for my atopic dermatitis prior to starting baricitinib	5% (8)
I requested a change because of something I had read/heard about a different treatment	9% (14)	Previously used systemic treatment^c	65% (110)
Treatment no longer paid for/covered by hospital/insurance	1% (1)
Other	2% (4)

^a Multiple selections were permitted for this question; therefore, prior treatments may have been used in combination.

^b Included Cyclosporine, Azathioprine, Methotrexate, Mycophenolate mofetil.

^c Including systemic corticosteroids, systemic immunosuppressant (oral or injection), and biologics.

Table 4. Change in concomitant topical treatment use.

	Treatment, % (n = 170)
Response	Topical corticosteroid	Topical calcineurin inhibitors	Emollients
Using more since starting baricitinib	3% (n = 5)	2% (n = 3)	2% (n = 4)
Using same amount since starting baricitinib	11% (n = 18)	2% (n = 4)	44% (n = 75)
Using less since starting baricitinib	50% (n = 85)	22% (n = 37)	44% (n = 74)
Not using anymore since starting baricitinib	32% (n = 55)	31% (n = 53)	3% (n = 5)
I have never used this treatment	4% (n = 7)	43% (n = 73)	7% (n = 12)

Figure 1. Patient global assessment of disease severity at baricitinib initiation and at survey completion (currently), including by subgroups for time on treatment and current dosage.

Figure 2. Patient satisfaction with baricitinib overall and by symptom dimension on a 4-point Likert scale.

Figure 3. Patient global impression of change overall and by treatment dimension with baricitinib treatment (n = 170).

Data availability statement

The datasets generated during and/or analyzed during the current study are not publicly available as consent was not received from participants for the sharing of their data with third parties.